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Abstract
Background The aim of this study is to present results of
the implantation of autologous myoblasts into the external
anal sphincter (EAS) in ten patients with fecal
incontinence.
Methods After anatomical and functional assessment of
the patients’ EAS, a vastus lateralis muscle open biopsy
was performed. Stem cells were extracted from the biopsy
specimens and cultured in vitro. Cell suspensions were then
administered to the EAS. Patients were scheduled for fol-
low-up visits in 6-week intervals. Total follow-up was
12 months.
Results All biopsy and cell implantation procedures were
performed without complications. Nine of the patients
completed a full 12-month follow-up. There was subjective
improvement in six patients (66.7 %). In manometric
examinations 18 weeks after implantation, squeeze anal
pressures and high-pressure zone length increased in all
patients, with particularly significant sphincter function
recovery in five patients (55.6 %). Electromyographic
(EMG) examination showed an increase in signal ampli-
tude in all patients, detecting elevated numbers of propa-
gating action potentials. Twelve months after implantation
two patients experienced deterioration of continence,
which was also reflected in the deterioration of manometric
and EMG parameters. The remaining four patients
(44.4 %) still described their continence as better than
before implantation and retained satisfactory functional
examination parameters.
Conclusions Implantation of autologous myoblasts gives
good short-term results not only in a subjective assessment,
but also in objective functional tests. It seems that this
promising technology can improve the quality of life of
patients with fecal incontinence, but further study is
required to achieve better and more persistent results.
Keywords Fecal incontinence  Electromyography  Anal
manometry  Stem cells  Myoblasts  Muscle regeneration
Introduction
The incidence of fecal incontinence in the general popu-
lation is estimated to be 2–15 %, increasing with age. It
drastically reduces quality of life and leads to reduction in
social activity and withdrawal from social and professional
life. Moreover, it leads to severe depression and anxiety
[1]. The healthcare costs associated with this disease are
enormous. The estimated cost of one patient treatment with
fecal incontinence exceeds $4000 per year [2].
The most common pathological mechanism of fecal
incontinence is the insufficiency of the external anal
sphincter (EAS) caused by neurological or myogenic dys-
function. The myogenic mechanism of EAS insufficiency
is usually due to direct mechanical damage during child-
birth, trauma or surgery in the anorectal region, whereas
the neurological mechanism involves damage to either the
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nerve. Unfortunately, coincidence of sphincter rupture with
damage to pudendal nerves is quite common [3].
There are many methods for treating fecal incontinence;
however, the efficacy of each of them is limited [4–10].
Conservative management, dietary and pharmacological
treatment and biofeedback training techniques give satis-
factory results only in patients with lower grades of
incontinence [5–7]. As for surgical methods, only some
patients achieve long-term satisfactory results. Overlapping
sphincteroplasty, a classical surgical treatment for sphinc-
ter damage, improves the clinical status of patients, but the
benefit is maintained only in half of the patients in long-
term follow-up [8–10].
Each skeletal muscle, including the EAS, has the ability
to regenerate (to some degree) and to repair damage sus-
tained. A special stem cells, called satellite cells, located
among the muscle fibers, are responsible for this phe-
nomenon. In response to injury and/or muscle damage,
satellite cells are activated and become myoblasts—ca-
pable of intense proliferation. Myoblasts then differentiate
and fuse together to form new muscle fibers and connect
with existing ones, adding new portions of contractile tis-
sue to existing motor units [11].
Isolated satellite cells in an undifferentiated state are
relatively easy to culture in vitro, and after implantation
they only differentiate into muscle cell lines, regardless
of the type of tissues in the vicinity, do not proliferate
more than necessary to repair the damaged muscle and
show no tendency toward malignant transformation.
Additionally, the use of autologous myoblasts is a way to
avoid problems related to possible immune rejection or
necessity of immunosuppression [12]. The technology of
in vitro myoblast culturing is being constantly improved
and is well documented in the scientific literature [12–
15].
Attempts at auto-transplantation of myoblasts into
damaged skeletal muscle have already been made in animal
models of muscular dystrophy [16], postinfarction
myocardial dysfunction [12, 17–19] and urethral sphincter
insufficiency [20]. Another example of effective cell ther-
apy using autologous myoblasts is the treatment of stress
urinary incontinence [21, 22]. The mechanism of this dis-
order very often involves failure of the external urethral
sphincter, with similar etiology as in fecal incontinence.
Some attempts have already been made to use autolo-
gous myoblast injections to augment the EASs, mostly on
animal models, but also on small groups of selected
patients [23, 24]. Based on those encouraging results, a
pioneer experimental study was designed in attempt to
enhance the function of the EAS using injections of
autologous muscle-derived stem cells, the myoblasts.
Materials and methods
The study was designed as a pilot prospective experimental
clinical trial. It was conducted by two cooperating facili-
ties—the 3rd Department of General Surgery, Jagiellonian
University in Krakow and the Department of Reproductive
Biology and Stem Cells, Institute of Human Genetics of the
Polish Academy of Sciences in Poznan. The study design
was approved by the Jagiellonian University Bioethics
Committee.
Patients with fecal incontinence due to sphincter insuf-
ficiency of various origin, who failed initial 6-month
biofeedback, were offered all appropriate treatment options
available in the 3rd Department of General Surgery,
Jagiellonian University, including stem-cell-based treat-
ment. Ten patients, who chose to undergo the autologous
myoblast implantation, were enrolled in this study. Written
informed consent was obtained from all patients.
Inclusion criteria include the following:
• age 18–75 years;
• moderate-to-severe fecal incontinence (Wexner score
[10);
• reduced basal and squeeze pressure on anorectal
manometry, with preserved anorectal reflexes [recto-
anal inhibitory reflex (RAIR) and rectal sphincter
contraction on cough (RSCC)] and anorectal sensation;
• preserved sphincter innervation based on properly
propagating action potentials of motor units shown in
sphincter electromyography;
• informed consent of the patient.
Exclusion criteria include the following:
• Fourth degree fecal incontinence (Wexner score = 20);
• EAS defect larger than 1/4 of sphincter circumference;
• EAS deinnervation, sensory deinnervation (neurogenic
etiology);
• advanced age ([75 years old);
• concomitant colorectal disorders [including rectocele,
intussusception, rectal prolapse, advanced hemor-
rhoidal disease (third–fourth degree)] or musculoskele-
tal disorders including lower extremity ischemia;
• other health disorders which could potentially increase
the risk of planned procedures (severe heart, lung,
hepatic or renal disorders, severe diabetes).
A total of one male and nine female patients with a
mean age of 43 years (range 20–68 years) were enrolled in
the study. The enrolled patients suffered from fecal
incontinence of varying degree and etiology (six with EAS
damage and four with idiopathic fecal incontinence). Apart
from subjective symptom assessments (Wexner and Fecal
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Incontinence Severity Index (FISI) questionnaires), a series
of examinations were performed:
• Anorectal manometry (MedtronicTM Polygraph
4-Channel Air-Charged Manometer). The following
parameters were recorded: mean resting pressure
(BAP), squeeze pressure (SAP) and high-pressure zone
length (HPZL).
• Surface endoanal electromyography (OTBioElettron-
ica, Turin, Italy). A 48-channel 3-ring endoanal probe
(Fig. 1) was used to obtain repetitive 10-s acquisitions
during rest and maximum contraction of the EAS. The
signal was analyzed visually for propagating action
potentials, and the following parameters were recorded:
mean root square of amplitude of motor unit action
potentials (ARV), mean signal frequency (MNF) and
median signal frequency (MDF). Also, dimensional
maps of signal strength were generated (Fig. 2).
• Endorectal ultrasound (ERUS). The external sphincter
muscle was assessed visually, with measurements of
muscle thickness and dimensions of any scarring or
defects present.
Under local anesthesia, a small incision of about 3 cm
was made on lower lateral side of the thigh, over the vastus
lateralis muscle (lateral head of the quadriceps of the
thigh). After preparation of tissues, the epimysium was
dissected and a 1-cm sample of muscle was harvested.
After careful hemostasis, the wound was closed with sur-
gical sutures. The specimens were sent to the Department
of Reproductive Biology and Stem Cells for in vitro cul-
turing of the myoblast cells.
The tissue fragment was mechanically dissected and
subjected to digestion with 0.02 % collagenase solution
(Sigma). The obtained cell suspension was filtered trough
80-lm mesh, centrifuged and plated on gelatine-covered
culture dish. Unless stated otherwise, Lonza supplied all
reagents used for in vitro culture media preparation. The
cells were kept in a 5 % CO2 atmosphere in 37 C in 95 %
humidity. Dulbecco’s modified Eagle’s medium (DMEM)
was supplemented with 20 % fetal bovine serum (FBS),
Ultraglutamine, antibiotic and antimycotic agents. To
facilitate the optimal proliferation environment and to
inhibit the spontaneous myocytes formation, the basic
fibroblast growth factor (bFGF) was provided (individually
tailored concentrations). The myoblasts were cultured up to
70 % confluence to avoid spontaneous cell fusion and
passaged every 4–5 days (altogether 7–10 passages), while
the medium was replaced every other day. The myoblasts
were mostly cultured for approximately 5.5 ± 0.8 weeks.
Efficiency of cell culture was evaluated after the final
passage of cells indicating the number of CD56 positive
cells as well as their myogenic characteristics by range of
gene expression in reverse transcription polymerase chain
reaction (RT-PCR). Also, the cell suspensions were tested
in routine microbial smears including mycoplasms. The
final number of cultured cells ranged from 50 to 600 9 106
(with a mean of 249 ± 68 9 106) from 1 cm of isolated
muscle tissue fragment.
To confirm myogenic properties of obtained cells, their
differentiation potential was assessed. Myocyte in vitro
formation was induced after cells reached 90 % conflu-
ence. The differentiation medium (DM) was supplemented
by 2 % horse serum instead of 20 % FBS and was deprived
of growth factors.
The CD56 expression [surface marker of neural, glial,
natural killer (NK) and also myogenic cells] was evaluated
using flow cytometry. Cells were stained with PE-Cy5TM
(PC5)-conjugated anti-CD56 antibody according to manu-
facturer’s protocol (Beckmann Coulter, Brea, CA, USA).
The cells were resuspended in 20 % FBS [in phosphate-
buffered saline (PBS)] and incubated with PC5-conjugated
anti-CD56 antibody for 20 min. After adding 2 % FBS
(diluted with PBS), the cells were centrifuged in 1200 rpm
for 5 min and the subsequent pellet was washed with 2 %
FBS solution (in PBS) and again centrifuged. Finally, the
cells were resuspended in 20 % FBS solution and 104 cells
were analyzed in the Cell Lab Quanta Cytometer (Beck-
mann Coulter, Brea, CA, USA).
Total ribonucleic acid (RNA) was extracted from
2 9 106 of cells according to the manufacturer’s protocol
of Trireagent (Sigma-Aldrich, St. Louis, MO, USA). Ten
micrograms of total RNA was used to purify messenger
(m) RNA fraction using Dynabeads mRNA Purification
Kit (Invitrogen Life Technologies, Carlsbad, CA, USA).
The reverse transcription reactions were performed in
standard conditions using Superscript reverse transcriptase
III (Invitrogen Life Technologies, Carlsbad, CA, USA).Fig. 1 Surface electromyography rectal probe
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The real-time PCR was performed using iQ SYBR Green
Supermix (Bio-Rad, Hercules, CA, USA).
The threshold cycle (Ct) values of each studied tran-
script were analyzed with iCycler iQ5 Real-Time PCR
Detection System (Bio-Rad Laboratories). All samples and
standard curve were run in duplicate. The relative expres-
sion level of each studied transcript (DES, MYOD1,
MYOG, MHC1, MRF4, MYF5) was normalized with ref-
erence to three housekeeping genes (ACTB, TBP, and
GAPDH) according to Vandesompele et al. [25]. Primer
sequences are summarized in Table 1.
The cell population before transplantation was analyzed
using Annexin V-FITC test. This assay evaluates the
number of apoptotic [with outer membrane-exposed
phospholipid phosphatidylserine (PS)] cells. Necrotic cells
were labeled with propidium iodide.
Cellular senescence is defined as growth arrest and cell
cycle exit. The myoblast population was kept over 5 weeks
in in vitro conditions, so there was a need to establish the
number of cells in sample population that reached their
proliferation limit. To analyze this process, the expression
of SA-beta-galactosidase was followed with the using of
X-Gal substrate. A staining kit based on histochemical
reaction was used (Senescence Detection Kit—Biovision)
according to manufacturer manual. Briefly, cells were fixed
and left overnight wit X-Gal staining solution in 37 C.
Fig. 2 Example of
electromyography before
implantation
Table 1 Primer sequences for all target genes used in real-time polymerase chain reaction
Gene ID Name of gene Primers Primer sequences (50 ? 30) Product size (bp)
ACTB b-Actin Forward CTTCCTGGGCATGGAGTCC 192
Reverse ATCTTGATCTTCATTGTGCTG
DES Desmin Forward CAGGTGGAGGTGCTCACTAAC 123
Reverse TGTTCTCTGCTTCTTCCTTCAAC
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Forward GCTCTCTGCTCCTCCTGTTC 112
Reverse ACCAAATCCGTTGACTCCGA
MHC1 Myosin heavy chain 1 Forward CCCTTGAGAAGACGAAGCAGAG 193
Reverse GTGAGCGGGATTCCTTTTGAG
MYF5 Myogenic factor 5 Forward TGCAGGAGTTGCTGAGAGAGCA 120
Reverse CAGGACTGTTACATTCGG
MYOD1 Myogenic differentiation 1 Forward ACGGCATGATGGACTACAG 212
Reverse CGACTCAGAAGGCACGTC
MYOG Myogenin Forward GCTGTATGAGACATCCCCCTA 226
Reverse CGACTTCCTCTTACACACCTTAC
MRF4 Myogenic regulatory factor 4 Forward CTTCAGCTACAGACCCAAACA 94
Reverse CCTGGAATGATCGGAAACAC
TBP TATA box binding protein Forward CATGACCCCCATCACTCCTG 196
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After 24 h, the blue color was developed in cells express-
ing SA-beta-galactosidase and the specimens were coun-
terstained with eosin to visualize the cytoplasm of all cells.
After preparation of the site, local anesthesia was
administered (1 % lidocaine s.c.) and a suspension of 108
myogenic stem cells per ml in DMEM with 1 % human
albumin was administered deep into the EAS under ERUS
guidance. Total volume of the suspension (about 3 ml) was
injected on entire circumference of the external sphincter
muscle ring (several injections about 1 cm apart). In
patients with a confirmed EAS defect, the total volume of
the suspension was divided into three 1-ml portions: 1 ml
was injected on both sides of the muscle scar, one was
applied on the remaining circumference of external
sphincter muscle ring (injections about 1 cm apart), and the
last portion was injected directly into the scar, so that the
bolus of injected fluid had direct contact with healthy
muscle tissue, creating a ‘‘bridge’’ between muscle ends,
across the scar. Patients went home the same day.
The patients were scheduled for 4 follow-up visits: at 6,
12, 18 weeks and 12 months after implantation. On each of
the follow-up visits, a series of examinations was per-
formed: anorectal manometry, surface endorectal EMG,
ERUS and questionnaire assessments.
The data were analyzed using StatSoft STATISTICA
software. Mann–Whitney U and Friedman ANOVA tests
were used to assess differences between measurements,
and Spearman correlation test was used for correlation
assessments.
Results
In the initial study group assessment, mean BAP was 34
mmHg, mean SAP was 63 mmHg, mean HPZL was 14.8
mm, while the mean Wexner score was 15 (range 12–18)
and the mean FISI score was 36 (range 29–45). EMG
assessment showed the presence of motor unit action
potentials in all patients, with visible gaps in the six
patients with EAS defects, confirmed by means of ERUS.
Tissue harvesting was performed under local anesthesia
and patients were discharged home the same day. Postop-
erative pain was easily controlled with oral paracetamol,
and none of the patients found the procedure inconvenient.
There were no complications of this procedure.
Implantation of the myoblast suspension was also per-
formed under local anesthesia, under direct ultrasound
guidance. There were no complications. One of the patients
reported mild discomfort in the perianal region, which
persisted a few hours after injection. The complaint
resolved spontaneously without further implications.
The cells obtained showed typical myoblast morphology
with in vitro myocyte formation evidenced by multinuclear
myotube presence (Fig. 3) and high proliferative potential.
After an average of 5.5 ± 0.8 weeks of in vitro culture,
from 50 to 600 9 106 cells (with a mean of
249 ± 68 9 106 from 1 cm of isolated muscle tissue
fragment) were prepared for the transplantation procedure.
A majority of cells presented surface CD56 marker; how-
ever, three different subgroups of patients could be
observed, those with a high CD56 expression (87 ± 4 %
cells), moderate expression (at the level of 60 ± 8 %) and
a low proportion of CD56 positive cells (below 50 %). We
also performed the validation of selected myogenic mark-
ers to analyze cell population characteristics. We observed
that the majority of examined cell populations presented a
medium intensity of desmin, whereas the MYOD1 and
MYOG protein expression showed rather heterogenous and
weak intensity (data unpublished). Thus, the myoblast
population was mostly determined as the proportion posi-
tive for CD56 marker, and there were also myogenic genes
expression by real-time PCR. We observed that each cell
population obtained was of myogenic origin, but at a dif-
ferent stage of cell differentiation, which suggests that
culture conditions were individual for each patient (Fig. 4).
The myoblast populations showed on average
16.94 ± 10.41 % of necrotic cells, whereas cells with
apoptotic characteristics stood for 1.87 ± 0.89 % of pop-
ulation. The evaluation of SA-beta-galactosidase expres-
sion showed that more than half of the cell population
Fig. 3 Representative micrographs indicate positive differentiation of patients’ myoblasts into myotubes. Black arrows indicate the
multinucleated cells under differentiation conditions
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(55.94 ± 24.82 %) besides a relatively long in vitro culture
retained their ‘‘young’’ characteristic. The presence of a
moderate level of beta-galactosidase positive cells was
observed in 39.84 ± 21.67 % of the cell population, while
only 4.22 ± 3.47 % of cells showed high expression of the
senescence indicator. At least 12 % of cells was defined as
Fig. 4 Examples of relative expression of myogenic genes for individual patients (6K–23K: patients’ unique identifiers)
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an actively proliferating population at cell transplantation
time-point (6.04 ± 3.64 in S phase and 6.11 ± 3.93 in G2
phase). All cell samples were capable of an efficient dif-
ferentiation process—fusion index (percentage of nuclei
incorporated in myotubes) estimated at 0.62 ± 0.18 %.
There was a significant negative correlation between the
patient’s age and number of cultured cells (Spearman
R = -0.7), which also needed significantly more time in
some cases to reach readiness for implantation.
Nine of the patients completed the full 12-month fol-
low-up (one patient refused to undergo further examina-
tions and was considered lost to follow-up). During the
first follow-up visit after 6 weeks, there were no signifi-
cant changes in manometric examinations regarding all
parameters, BAP, squeeze pressure SAP, and HPZL,
although some patients reported subjective improvement
in questionnaire evaluation. The site of implantation
showed no signs of edema, nor was there any significant
difference in ultrasound assessment. At the following
visits (12 and 18 weeks after implantation), SAP and
HPZL were gradually increasing (Figs. 5, 6, 7), as scores
in incontinence questionnaires were decreasing (Figs. 8,
9). There was also a slight increase in BAP. After
18 weeks of follow-up, SAP was significantly increased in
most patients (on average by 20.5 mmHg), with a mean
relative increase 38.3 % of the initial pressures (Friedman
p\ 0.05). HPZL was significantly longer (average
increase of 6.7 mm), and the mean relative increase was
51.7 % of the initial values (Friedman p\ 0.05). The
increase in BAP, although less intense, also reached sta-
tistical significance. Mean values of the measurements are
presented in Table 2.
In a case-by-case analysis after 18 weeks, significant
subjective improvement was obtained in six patients
(66.7 %). In manometric examinations, SAP and HPZL
Fig. 5 Resting pressure (BAP) in cmH2O initially and after 6, 12, 18
weeks and 12 months
Fig. 6 Squeeze pressure (SAP) in cmH2O initially and after 6, 12, 18
weeks and 12 months
Fig. 7 High-pressure zone length (HPZL) in cm initially and after 6,
12, 18 weeks and 12 months
Fig. 8 Fecal Incontinence Severity Index (FISI) score—initially and
after 6, 12, 18 weeks and 12 months
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increased in all patients, with a particularly significant
increase in five patients (55.6 %).
EMG showed significant increase in signal amplitude
(ARV) in all patients (Fig. 10), detecting an increased
number of propagating action potentials (average increase
by 60.3 % of the initial voltage value, Friedman ANOVA
p\ 0.05). There was also a significant change in mean or
median frequency of the signal: Signal-to-noise ratio after
implantation changed in favor of properly propagating
motor unit action potentials (Fig. 11). Dimensional power
map analysis also showed a general increase in signal
amplitude (marked as ‘‘2’’ in Fig. 12). Moreover, in
patients with signal gaps (scar tissue, without conductive or
contractile abilities) action potentials appeared in previ-
ously inactive parts of the sphincter’s circumference
(marked as ‘‘1’’ in Fig. 12).
Twelve months after implantation, a deterioration of
continence was reported by two of the six patients who
achieved good results at 18 weeks. This was also reflected
in the deterioration of manometric (BAP, SAP, HPZL) and
EMG parameters (Figs. 5, 6, 7, 10, 11). Nevertheless, mean
values were still significantly better than before the
implantation. The remaining four patients (44.4 %) con-
tinued to have satisfactory results after 12 months, with
reduction in frequency and intensity. Case-by-case analysis
of the EMG signal showed that patients who achieved good
end results had higher initial amplitude of action potentials
(ARV measured before implantation) than those with poor
Table 2 Comparison of
manometry (BAP, SAP, HPZL),
questionnaire (FISI, Wexner)
and EMG values before
implantation and 6, 12, 18
weeks and 12 months after
implantation. Results are mean
values
Initial 6 weeks 12 weeks 18 weeks 12 months
BAP (cmH2O) 34.78 35.56 40.89 47.11 44.22
SAP (cmH2O) 63.56 70.00 79.33 84.11 85.44
HPZL (cm) 1.49 1.57 2.03 2.17 1.91
FISI 36.67 28.89 27.44 26.67 28.11
Wexner 14.33 10.89 9.67 8.33 9.89
EMG amplitude (lV) 5.80 7.43 8.63 9.88 8.50
EMG frequency (Hz) 96.78 91.81 88.24 85.94 91.00
BAP resting anal pressure, SAP squeeze pressure, HPZL high-pressure zone length, FISI Fecal Incontinence
Severity Index, EMG electromyography
Fig. 9 Wexner score—initially and after 6, 12, 18 weeks and 12
months
Fig. 10 Electromyography signal amplitude (IARV) in lV initially
and after 6, 12, 18 weeks and 12 months
Fig. 11 EMG signal frequency (IMNF) in Hz initially and after 6, 12,
18 weeks and 12 months
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Fig. 12 Example of electromyography power map—comparison of
before (top) and 18 weeks after implantation (bottom). The darker the
blue color, the stronger the electrical activity. Low activity on the
right circumference of superficial part of the sphincter (leftmost ring)
was due to external sphincter scarring and probable right-sided
pudendopathy. Note electrical activity regained after implantation in
previously inactive parts (1) and general increase in signal strength in
undamaged muscle tissue (2)
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or not persistent results (Mann–Whitney U test, p\ 0.05)
(Fig. 13).
Discussion
Despite great interest in stem cells in general, there have been
very few trials attempting to aid regenerative capabilities of
human striated muscles. A damaged or weakened EAS is
particularly difficult to strengthen without risky surgical
intervention, and the only noninvasive method of EAS
regeneration so far was biofeedback training, which, as
shown by the literature, provided ambivalent results [7].
Implantation of autologous myoblasts may potentially not
only improve general functioning of the EAS, but, by intro-
duction of ‘‘fresh’’ muscle fibers, might increase the amount
of contractile tissue in this region, thus improving the effect
of various physiotherapeutic and behavioral treatments.
However, myocytes that differentiate from those stem
cells require that the pelvic floor is sufficiently innervated
to function properly, otherwise they would deteriorate with
time [26]. In a pilot study by Frudinger et al. [24], autol-
ogous myoblasts were used in the treatment of anal
incontinence due to obstetric anal sphincter injury, but the
results evaluated by means of a questionnaire, manometric
and ultrasound examinations were inconsistent and most
strongly marked in subjective questionnaire assessment. In
our study, patients also reported subjective improvement
soon after implantation, even though no other test had
shown any change yet, and there was no edema or other
signs which might suggest a ‘‘bulking effect’’ of the
injection itself (by the time of the 6-week visit, the sus-
pension had been already completely absorbed). This led us
to conclude that it is the placebo effect that might have
been the key factor in the improvement of patients’ quality
of life early after the procedure and questionnaires should
be analyzed in the context of other tests. One of the
methods of increasing the reliability of results that is used
in many studies is anorectal manometry. There is strong
supportive evidence in the literature for the use of anorectal
manometry as a method of sphincter function assessment,
and the importance of manometry assessment of colorectal
surgery patients is only rarely contested [27–29]. Unfor-
tunately, it gives no information about pudendopathy or
other neurological conditions, potentially coexisting with
sphincter damage. As for ERUS, it turned out to be even
more subjective, as interpretation of results was very
inconsistent and heavily depended on the opinion of the
physician performing the examination. The only measur-
able variables in this examination, sphincter dimensions
and sphincter scar dimensions, did not change significantly,
and as a result, we excluded ultrasonography-related
parameters from our analysis, as they did not provide any
valuable information.
Taking all the above into consideration, all patients
enrolled into our study group underwent surface endoanal
EMG. The reliability of this noninvasive method of
innervation assessment has been recently proved in several
clinical and experimental studies [30–35]. The pelvic floor
innervation of all the patients enrolled in our study was
preserved, although to various degrees. The retrospective
analysis of our data showed that the patients who had a
weak response to the treatment or reported deterioration of
initial positive effects had in fact low amplitude of motor
units’ action potentials in initial examination, although the
group was too small to show strong statistical correlation.
There are several limitations to our study. A small group
of subjects is an obvious drawback. Moreover, there was no
control group, because the limited number of patients who
agreed to participate in the study made it impossible to
perform a proper randomized controlled trial.
On the other hand, valuable result of this study was the
EMG evidence of motor units’ action potentials gradually
appearing in regions previously lacking of conductive and
contractile capabilities, which may be a ‘‘proof of concept’’
that implanted myoblasts not only differentiated into
myocytes, but were able to ‘‘plug-in’’ to existing motor
units, with the result that individual motor neurons had
more muscle tissue at their disposal.
Conclusions
Implantation of autologous myoblasts gives good short-
term results not only in a subjective assessment, but also in
objective functional tests. Proper innervation of the EAS
seems to be a crucial factor influencing final results. This
Fig. 13 Comparison of electromyography signal amplitude (IARV)
in Hz before implantation in patients who did and did not achieve
satisfactory results
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promising technology can give a chance to improve the
quality of life of patients with fecal incontinence, but it
requires further study to achieve better and more persistent
results, preferably in a controlled trial on larger groups of
patients.
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